Stoke Therapeutics STOK 深 沪
等待开盘 04-02 09:30:00 美东时间
31.99
-0.570
-1.75%
华盛通- 最 高34.38
- 今 开32.66
- 成交量 68.62万股
- 最 低 31.38
- 昨 收 32.56
- 总市值 18.92亿
- 52周最高 40.22
- 市盈率 静 --
- 换手率 1.16%
- 52周最低 6.89
- 委 比 -10.71%
- 总股本 5915.08万
- 历史最高 71.58
- 量 比 0.55
- 振 幅 9.21%
- 历史最低 3.35
- 每 手 1
- 风险率 10.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
美股大行评级 | 最高700美元！大摩、瑞银等10家大行集体上调美光目标价；通用磨坊、梅西百货、SailPoint等遭多家大行下调目标价
今日重点评级关注：RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从32美元升至35美元；巴克莱：维持CytomX医疗"超配"评级，目标价从10美元升至16美元
03-20 15:53
U.S. RESEARCH ROUNDUP- Air Products, Chevron, Fedex
U.S. RESEARCH ROUNDUP- Air Products, Chevron, Fedex March 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Air Products, Chevron and Fedex on Friday. HIGHLIGHTS * Air Products APD.N : JP Morgan raises to overweight fro
03-20 14:50
美股大行评级 | 摩根大通上调哔哩哔哩至"超配"，目标价从27美元升至35美元；Rhythm遭花旗、大摩等多家机构下调目标价
今日重点评级关注：韦德布什：维持Black Diamond Therapeutic"跑赢大市"评级，目标价从13美元升至14美元；花旗：维持Olema Pharmaceuticals"买入"评级，目标价从60美元升至62美元
03-18 10:48
Semtech To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday
Wall Street analysts changed outlook on top names: Morgan Stanley raised Lemonade's PT to $85, Mizuho cut Canadian Solar's PT to $19, Piper Sandler raised Tandem Diabetes' PT to $33, Stifel increased Ichor's PT to $55, Needham raised Semtech's PT to $105, HC Wainwright cut Eupraxia Pharma's PT to $11, Evercore ISI Group raised National Storage Affiliates Trust's PT to $41.
03-17 19:49
Needham Maintains Buy on Stoke Therapeutics, Raises Price Target to $40
Needham analyst Joseph Stringer maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and raises the price target from $35 to $40.
03-17 19:13
Stoke Therapeutics And Biogen Report NEJM Data Showing Zorevunersen May Modify Disease In Dravet Syndrome, Supporting Phase 3 EMPEROR Study
–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease––Data support ongoing global Phase 3
03-05 06:07
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
NervGen Pharma Corp. has appointed Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as Senior Vice President of Patient Advocacy and Clinical Affairs. Both bring extensive experience to support NervGen's lead therapeutic, NVG-291, which is advancing through clinical trials for spinal cord injury (SCI). Ruff, with over 30 years in regulatory affairs, will oversee the company's regulatory strategy, while McSherry will ensure p...
03-04 12:30
美股大行评级 | 潜在涨幅243.25%！泰利克斯制药获花旗升目标价至22.5美元，维持"买入"评级
今日重点评级关注：花旗：维持Telix Pharmaceuticals"买入"评级，目标价从22美元升至22.5美元；摩根士丹利：维持Vir Biotechnology"超配"评级，目标价从20美元升至24美元
02-25 11:03
Wolfe Research Initiates Coverage On Stoke Therapeutics with Outperform Rating, Announces Price Target of $40
Wolfe Research analyst Rudy Li initiates coverage on Stoke Therapeutics (NASDAQ:STOK) with a Outperform rating and announces Price Target of $40.
02-24 20:22
